5.15% -0.1543

Dopo l'orario di chiusura: 2.81 -0.03 -1.06%

Tharimmune Inc (THAR)

Tharimmune Inc Borsa (THAR) Ultime notizie

Tharimmune Inc (THAR)

Tharimmune Inc Borsa (THAR) Ultime notizie

Tharimmune Expands Immunology Pipeline with Intract License - TipRanks

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab - StockTitan

Tharimmune, Inc. (NASDAQ:THAR) Short Interest Down 35.7% in July - Defense World

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory BoardChannel3000.com - Channel3000.com - WISC-TV3

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board - StockTitan

Tharimmune adds David Clarke as Strategic Advisor - Investing.com

Tharimmune launches new website amid continuing discussions wtih FDA - TipRanks

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor - StockTitan

Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104 - StockTitan

Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update - Defense World

Tharimmune names industry veteran Haimovitz as strategic advisor - Investing.com

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor - StockTitan

Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com Australia

Tharimmune to sell 659,545 shares at $3.16 in private placementTipRanks.com - TipRanks

Tharimmune raises $2.08 million in private placement - Investing.com India

Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com

Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com UK

Tharimmune Announces $2.08 Million Private Placement | THAR Stock News - StockTitan

Tharimmune Announces $2.08 Million Private Placement - StockTitan

Tharimmune announces Type C meeting with FDA for Phase 2 TH104 programTipRanks.com - TipRanks

THAR: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle

FDA nods to Tharimmune's Phase 2 itch relief trial plan By Investing.com - Investing.com

FDA nods to Tharimmune's Phase 2 itch relief trial plan - Investing.com India

FDA nods to Tharimmune's Phase 2 itch relief trial plan - Investing.com South Africa

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for ... - StockTitan

FDA nods to Tharimmune's Phase 2 itch relief trial plan - Investing.com

Tharimmune announces results of Phase 1 trial of TH104TipRanks.com - TipRanks

Tharimmune (THAR) Reports Positive Results of Phase 1 Trial in Healthy Subjects with TH104 - StreetInsider.com

Why Tharimmune (THAR) Shares Are Getting Hammered - MSN

Tharimmune reports promising Phase 1 results for TH104 By Investing.com - Investing.com Canada

Tharimmune reports promising Phase 1 results for TH104 By Investing.com - Investing.com

Why Tharimmune (THAR) Shares Are Getting HammeredTharimmune (NASDAQ:THAR) - Benzinga

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for ... - Yahoo Finance

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis - AccessWire

U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.55% - MSN

Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Drops By 83.2% - MarketBeat

Investor's Toolkit: Key Ratios for Assessing Tharimmune Inc (THAR)'s Performance – DWinneX - The Dwinnex

Why Is Tharimmune (THAR) Stock Moving Today? - MSN

Prepare Yourself for Liftoff: Tharimmune Inc (THAR) – Sete News - SETE News

Why Is Tharimmune (THAR) Stock Moving Today? - InvestorPlace

Tharimmune Stock Set to Reverse Split on Tuesday, May 28th (NASDAQ:THAR) - Defense World

Tharimmune announces 1-for-15 reverse stock splitTipRanks.com - TipRanks

Upward Trajectory: Tharimmune Inc (THAR) Posts a Slidee, Closing at 0.33 – DWinneX - The Dwinnex

Tharimmune Inc (THAR) Stock: A Year of Decreases and Increases - The InvestChronicle

Tharimmune announces 1-for-15 reverse stock split By Investing.com - Investing.com

Tharimmune announces 1-for-15 reverse stock split By Investing.com - Investing.com UK

Why Tharimmune (THAR) Shares Are MovingTharimmune (NASDAQ:THAR) - Benzinga

Tharimmune (NASDAQ:THAR) Stock Price Up 3.9% - Defense World

Tharimmune announces 1-for-15 reverse stock split - Investing.com

THAR Stock Earnings: Tharimmune Reported Results for Q4 2023 - MSN

THAR Stock Earnings: Tharimmune Reported Results for Q4 2023 - InvestorPlace

Tharimmune enters option agreement with Washington UniversityTipRanks.com - TipRanks

Tharimmune Announces Option For Novel HER2/HER3 Cancer Therapies - Contract Pharma

Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now - GlobeNewswire

Tharimmune's buccal film liver drug demonstrates effectiveness in Phase I trial - Clinical Trials Arena

CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients - Yahoo Finance

Why Is Tharimmune (THAR) Stock Down 70% Today? - InvestorPlace

Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug (NASDAQ:THAR) - Seeking Alpha

Tharimmune (NASDAQ: THAR) to jump 2,500%purely technical and nominal - Dhaka Tribune

Why Is Tharimmune (THAR) Stock Down 8% Today? - InvestorPlace

THARTharimmune, Inc. Latest Stock News & Market Updates - StockTitan

Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today? - InvestorPlace

Why Is Tharimmune (THAR) Stock Up 54% Today? - InvestorPlace

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. - Yahoo Finance

Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data - StockTitan

Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023 - StockTitan

Simile a THAR